Literature DB >> 17847103

Influence of sample matrix and storage on BNP measurement on the Bayer Advia Centaur.

Giuseppe Lippi1, Antonio Fortunato, Gian Luca Salvagno, Martina Montagnana, Giuliano Soffiati, Gian Cesare Guidi.   

Abstract

The assessment and management of congestive heart failure relies increasingly on the measurement of B-type natriuretic peptide (BNP). However, the effective contribution of this biochemical test in the clinical decision making is influenced by reliability of the measure, which also depends on several preanalytical issues. Since there is controversy on the influence of the matrix and the storage conditions on BNP measurement, we compared results of BNP in serum, K2 ethylene diamine tetra-acetic acid (EDTA) plasma and lithium heparin plasma fresh samples and in matching samples stored at -20 and -80 degrees C for 1 week. BNP measured on the Bayer Advia Centaur was systematically underestimated in heparin plasma (-47%) and serum (-62%) when compared to K2 EDTA plasma. According to the established 100 ng/L cutoff value, 25% and 37% of the fresh samples collected in heparin plasma or serum were misclassified from the reference K2 EDTA fresh specimen, respectively. When compared to the fresh specimens, the mean and interindividual bias observed for samples stored at either -20 degrees C or -80 degrees C was, overall, modest for K2 EDTA plasma (-2%) and heparin plasma (+6% and -4%, respectively), though it appeared clinically meaningful in serum (+47% and +28%, respectively). Although we can not rule out that other BNP assays using different antibodies may be not affected from degradation during storage to the same extent, results of our investigation demonstrate that K2 EDTA plasma is the most suitable specimens for BNP testing on fresh and frozen samples stored at either -20 degrees C or -80 degrees C for up to 1 week. (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17847103      PMCID: PMC6649196          DOI: 10.1002/jcla.20187

Source DB:  PubMed          Journal:  J Clin Lab Anal        ISSN: 0887-8013            Impact factor:   2.352


  23 in total

Review 1.  BNP for clinical monitoring of heart failure.

Authors:  Richard W Troughton; A Mark Richards
Journal:  Heart Fail Clin       Date:  2006-07       Impact factor: 3.179

2.  N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease.

Authors:  Charlotte Kragelund; Bjørn Grønning; Lars Køber; Per Hildebrandt; Rolf Steffensen
Journal:  N Engl J Med       Date:  2005-02-17       Impact factor: 91.245

3.  Stabilization of human brain natriuretic peptide in blood samples.

Authors:  T Tsuji; K Imagawa; H Masuda; M Haraikawa; K Shibata; M Kono; K Inouye; K Uchida
Journal:  Clin Chem       Date:  1994-04       Impact factor: 8.327

4.  Stability of brain natriuretic peptide (BNP) in human whole blood and plasma.

Authors:  A Gobinet-Georges; N Valli; H Filliatre; M F Dubernet; O Dedeystere; L Bordenave
Journal:  Clin Chem Lab Med       Date:  2000-06       Impact factor: 3.694

5.  Heparin plasma sampling as an alternative to EDTA for BNP determination on the Access-Beckman Coulter--effect of storage at -20 degrees C.

Authors:  Anne Marie Dupuy; Nathalie Terrier; Marjorie Dubois; Anne Marie Boularan; Jean Paul Cristol
Journal:  Clin Lab       Date:  2006       Impact factor: 1.138

Review 6.  Comparison of the diagnostic accuracy of brain natriuretic peptide (BNP) and the N-terminal part of the propeptide of BNP immunoassays in chronic and acute heart failure: a systematic review.

Authors:  Aldo Clerico; Marianna Fontana; Luc Zyw; Claudio Passino; Michele Emdin
Journal:  Clin Chem       Date:  2007-03-23       Impact factor: 8.327

Review 7.  Serial testing of B-type natriuretic peptide and NTpro-BNP for monitoring therapy of heart failure: the role of biologic variation in the interpretation of results.

Authors:  Alan H B Wu
Journal:  Am Heart J       Date:  2006-11       Impact factor: 4.749

Review 8.  The role of ethylenediamine tetraacetic acid (EDTA) as in vitro anticoagulant for diagnostic purposes.

Authors:  Giuseppe Banfi; Gian Luca Salvagno; Giuseppe Lippi
Journal:  Clin Chem Lab Med       Date:  2007       Impact factor: 3.694

9.  Analytical and clinical evaluation of the Bayer ADVIA Centaur automated B-type natriuretic peptide assay in patients with heart failure: a multisite study.

Authors:  Alan H B Wu; Milton Packer; Andrew Smith; Rachel Bijou; Daniel Fink; Johannes Mair; Lars Wallentin; Nina Johnston; Carolyn S Feldcamp; Doris M Haverstick; Charaf E Ahnadi; Andrew Grant; Normand Despres; Barry Bluestein; Farooq Ghani
Journal:  Clin Chem       Date:  2004-03-09       Impact factor: 8.327

10.  Short-term serial sampling of natriuretic peptides in patients presenting with chest pain.

Authors:  Gene Kwan; Susan R Isakson; Jennifer Beede; Paul Clopton; Alan S Maisel; Robert L Fitzgerald
Journal:  J Am Coll Cardiol       Date:  2007-03-06       Impact factor: 24.094

View more
  2 in total

Review 1.  Pre-analytic variability in cardiovascular biomarker testing.

Authors:  Roberto Cemin; Massimo Daves
Journal:  J Thorac Dis       Date:  2015-10       Impact factor: 2.895

Review 2.  Understanding preanalytical variables and their effects on clinical biomarkers of oncology and immunotherapy.

Authors:  Lokesh Agrawal; Kelly B Engel; Sarah R Greytak; Helen M Moore
Journal:  Semin Cancer Biol       Date:  2017-12-16       Impact factor: 15.707

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.